

REMARKS/ARGUMENTS

In the Communication mailed 23 March 2005, the Examiner indicated that the reply filed 3 January 2005 was not fully responsive to the previous office action, as claims 28, 30, 32, 33, and 36-38 depended from cancelled claim 2. In this supplemental response, claim 28 has been amended to depend from claim 4. Claims 30, 32, 33, and 36-38 depend from claim 28, either directly or indirectly. It is now maintained that claims 28, 30, 32, 33, and 36-38 depend from an allowable claim and therefore, are also allowable. The remaining amendments and arguments, previously presented in the response of 3 January 2005, are presented again herein to provide a complete response to the Office Action of 28 September 2004.

Claims 1-56 were pending at the time of the mailing of the outstanding Office Action. Claims 14-27 and 46-56 have been withdrawn from consideration. By this amendment, claims 2, 7, 11, 39-41 and 44-45 have been cancelled without prejudice or disclaimer as to the subject matter contained therein. Claims 1, 4, 8-9, 12-13, 28 and 42-43 have been amended. No new claims have been added. In light of the withdrawal of claims 15 and 16, paragraph [0008], has been amended to eliminate reference to claims 15 and 16 *per se*, in favor of reciting the subject matter of those claims.

In the Office Action of 28 September 2004, the Examiner rejected claims 1-8, 10-13, 28-38 and 40-45 under 35 U.S.C. § 102(b) as being anticipated by U.S. Patent No. 6,561,968 to Dissing, et al. Claims 1-5, 7-13, 28-33 and 39-45 stand rejected as being anticipated by U.S. Patent No. 3,890,953 to Kraus, et al. Claims 1-8, 10-13, 28-38 and 40-45 stand rejected as anticipated by U.S. Patent No. 4,674,482 to Waltonen, et al. Finally claims 1-2, 7-8, 10-13, 29 and 40-45 stand rejected as being anticipated by U.S. Patent No. 5,211,622 to Liboff, et al. or U.S. Patent No. 5,718,2436 to Vona.

To anticipate a claim, a reference must teach all elements of the claim (MPEP § 2131). Claim 1 has been amended to recite the presence of an implant, adapted to be

placed in a blood vessel, contactlessly receive stimulation energy from the excitation device and produce stimulation currents. Support for this amendment can be found in the specification in paragraph 20 and in original claims 2, 11 and 41, now cancelled. While the Examiner previously indicated that the limitations of claims 11-13 provide statements of intended use, the amendment to claim 1 recites additional structure of the device, and not its intended use. Claim 1, as amended, patentably distinguishes over the cited prior art. Specifically, Dissing et al do not teach or suggest an implant, adapted to be placed in a blood vessel, contactlessly receive stimulation energy from a stimulation device and produce stimulation currents. Kraus et al provide a device which applies a magnetic field to a bone to promote growth but they do not provide an implant adapted to be placed in a blood vessel to be used in such a system. Waltonen et al provide a device for applying a magnetic field to animal tissue to promote healing, but do not teach or suggest the use of an implant to contactlessly receive stimulation energy and to produce a stimulation current. Finally, Waltonen et al and Vona provide methods for treating cells with magnetic fields, but these methods also do not teach or suggest the use of implants adapted to be placed in a blood vessel, contactlessly receive stimulation energy and produce a stimulation current. Therefore, it is maintained that claim 1 patentably distinguishes over the cited prior art. Likewise, claims 3-6, 8-10, 12-13, 28-38, and 42-43, which directly or indirectly depend from and include all the limitations of claim 1, also patentably distinguish over the cited prior art.

The outstanding Communication was mailed on 23 March 2005. The Examiner set a shortened statutory period for reply of 1 month or 30 days from the mailing date. Therefore, no petition for an extension of time or accompanying fee is believed to be due in making this response. In this response, claims 2, 7, 11, 40-41, and 44-45 have been cancelled and no claims have been added. Therefore, no additional claim fees are believed to be due. However, in the event that a fee for the filing of his response is insufficient, the Commissioner is authorized to charge any fee deficiency or to credit any overpayment to Deposit Account 15-0450.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "John J. Cunniff". The signature is fluid and cursive, with a long horizontal stroke at the end.

John J. Cunniff
Reg. No 42,451
Hahn Loeser + Parks LLP
One GOJO Plaza, Suite 300
Akron, OH 44311

Attorney for Applicants